Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT
International Journal of Molecular Imaging · 2011
DOI: 10.1155/2011/524130 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Imaging, 2011. Verfasst von Sowon Oh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, College of Medicine, Seoul National University, Seoul 151-742, Republic of Korea. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
The heterogeneous nature of the neuroendocrine tumors (NET) makes it challenging to find one uniformly applicable management protocol which is especially true for diagnosis. The discovery of the overexpression of somatostatin receptors (SMS-R) on neuroendocrine tumor cells lead to the generalized and rapid acceptance of radiolabeled somatostatin receptor analogs for staging and restaging of NET as well as for Peptide Receptor Radionuclide Therapy (PRRNT) using Y-90 and Lu-177 DOTATATE/DOTATOC. In this present work we tried to look in to the effect of PRRNT on the glucose metabolism assessed by F-18 FDG PET/CT and SMS-R density assessed by Ga-68 DOTANOC PET/CT. We observed a complex relationship between the somatostatin receptor expression and glucose metabolism with only 56% (77/138) of the lesions showing match, while the others show mismatch between the receptor status and metabolism. The match between receptor expression and glucose metabolism increases with the grade of NET. In grade 3 NET, there is a concurrence between the changes in glucose metabolism and somatostatin receptor expression. PRRNT was found to be more effective in lesions with higher receptor expression.
Autor:innen und Institutionen
- Department of Nuclear Medicine, College of Medicine, Seoul National University, Seoul 151-742, Republic of Korea.
Zitieren
APA
Oh, S., Prasad, V., Lee, D. S., & Baum, R. P. (2011). Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT. International Journal of Molecular Imaging. https://doi.org/10.1155/2011/524130
Vancouver
Oh S, Prasad V, Lee DS, Baum RP. Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT. International Journal of Molecular Imaging. 2011. doi:10.1155/2011/524130
BibTeX
@article{Oh2011,
author = {Oh, Sowon and Prasad, Vikas and Lee, Dong Soo and Baum, R P},
title = {Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT},
journal = {International Journal of Molecular Imaging},
year = {2011},
doi = {10.1155/2011/524130}
}
EUVIMED